Table 1. The clinical characteristics of patients in different cohorts.
| Variable | Total (n = 414) | Train (n = 290) | Validate (n = 124) | Statistic | P |
| Gender, n (%) | |||||
| Female | 172 (43.43) | 123 (44.40) | 49 (41.18) | χ² = 0.353 | 0.552 |
| Male | 224 (56.57) | 154 (55.60) | 70 (58.82) | ||
| Age, M (Q1, Q3) | 62.50 (52.00–73.75) | 64.00 (52.00–74.00) | 59.00 (v49.00–72.00) | Z = 2.058 | 0.040 |
| LDH ratio, M (Q1, Q3) | 1.01 (0.77–1.62) | 1.01 (0.78–1.68) | 1.01 (0.75–1.44) | Z = 0.419 | 0.675 |
| Clinical diagnosis, n (%) | |||||
| ABC DLBCL | 167 (40.34) | 123 (42.41) | 44 (35.48) | χ² = 2.809 | 0.245 |
| GCB DLBCL | 183 (44.2) | 127 (43.79) | 56 (45.16) | ||
| Unclassified DLBCL | 64 (15.46) | 40 (13.79) | 24 (19.35) | ||
| ECOG performance status, n (%) | |||||
| 0 | 85 (21.85) | 57 (21.03) | 28 (23.73) | χ² = 4.870 | 0.301 |
| 1 | 211 (54.24) | 152 (56.09) | 59 (50.00) | ||
| 2 | 60 (15.42) | 37 (13.65) | 23 (19.49) | ||
| 3 | 28 (7.2) | 20 (7.38) | 8 (6.78) | ||
| 4 | 5 (1.29) | 5 (1.85) | 0 (0.00) | ||
| Stage, n (%) | |||||
| 1 | 66 (16.26) | 45 (15.79) | 21 (17.36) | χ² = 1.623 | 0.654 |
| 2 | 122 (30.05) | 83 (29.12) | 39 (32.23) | ||
| 3 | 97 (23.89) | 73 (25.61) | 24 (19.83) | ||
| 4 | 121 (29.8) | 84 (29.47) | 37 (30.58) | ||
| Risk score, M (Q1, Q3) | 1.00 (0.73–1.36) | 0.99 (0.76–1.35) | 1.06 (0.71–1.36) | Z = 0.339 | 0.734 |